PTO/SB/08B (09-05)

Approved for use through 03/31/2007, OMB 0551-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449PTO	Complete if Known		
	Application Number	10/574,054	
INFORMATION DISCLOSURE	Filing Date	March 29, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Shue, Youe-Kong	
(Use as many sheets as necessary)	Art Unit	TBA	
(Examiner Name	TBA	
Sheet 1 of 3	Attorney Docket Number	8031-013-US	

NON PATENT LITERATURE DOCUMENTS

Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), tibe of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AYRAL, et. al. Rheumatology, Vol 35, 14-17	Г
		AYRAL, et. al. Annals of the Rheumatic Diseases 2002 vol. 61 suppl. 1	Г
		HUGHES, et. al. Rheumatology (Oxford) 2002; 41:279-84	Т
		HEDBOM, et. al. Cell Mol Life Sci 2002; 59:45-53	
		AMIEL et. al. J Orthop Res 1986; 4:162-172	
		ALTMAN et. al. Am J Med. 1983 Oct 31;75(4B):50-5	
		ADEBOWALE et. al. Biopharm Drug Dispos 2002; 23:217-25	
		AGHAZADEH-HABASHI et. al. J Pharm Pharm Sci 2002; 5(2):181-4	
		CHANG et. al. Osteoarthritis Cartilage 1997; Sep;5:357-72	Г
		DE MATTEI et. al. Osteoarthritis Cartilage 2002; 10:816-25	Г

Examiner Signature		Date Considered	
EXAMINER; I	vital if reference considered, whether or not offation is in conformance with MPEP 60	9. Draw line through o	flation if not in conformance and not

considered. Include copy of this form with next communication to epplicant.

considered. Fooder Gooy of the form with none communication to explaned.

Fooder fooder good of the form with none communication to explaned.

Fooders fooder good consideration are reported. Popular and the business a desirable management of the fooders of inflamentation in explaned by 19 CPF LCS. The illustration in explaned by the fooders of inflamentation in explaned by 19 CPF LCS. The illustration in explaned by the fooders of inflamentation in explaned by 19 CPF LCS. The illustration in explaned by 19 CPF LCS. The illustration is explaned missioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTG/SB/03B (09-05)
Approved for use through 03/31/2007. CMB 0651-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTQ	Complete If Known		
	Application Number	10/574,054	
INFORMATION DISCLOSURE		March 29, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Shue, Youe-Kong	
(Use as many sheets as necessary)	Art Unit	TBA	
[control of the cont	Examiner Name	TBA	
Sheet 2 of 3	Attorney Docket Number	8031-013-US	

NON PATENT LITERATURE DOCUMENTS

Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ELSAID et. al. Osteoarthritis Cartilage. 2003;11:673-80	
		FINGL et al., in The Pharmacological Basis of Therapeutics, 1975, Ch. 1 p. 1	
		GELETKA et. al. Best Pract Res Clin Rheumatol. 2003 Oct;17:791-809	
		KERIN et. al. Cell Mol Life Sci 2002;59:27-35	
		REGINSTER et. al. Lancet 2001; 357:251-6	
		REISSIG et. al. J. Biol. Chem. 1955 217: 959-966	
		MCALINDON, Best Pract Res Clin Rheumatol 1999; 13(2):329-44	
		SANDY et. al. Arch Biochem Biophys 1999; 367:258-64	Т
		SHIKHMAN et. al. J Immunol 2001; 166:5155-60	
		SETTON et. al. Osteoarthritis Cartilage 1999; 7:2-14	

Examiner	D	Date	
Signature	15		
		Considered	
"EXAMINER: Initial if reference considered, w	ether or not attrition is in conformance with MPEP 609. D	Draw line through o	tation if not in conformance and not

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in cont considered. Include copy of this form with next communication to applicant.

concloses. On Child Golg of this form with ori communication to spiciate.

The Child Golg of this form with not communication to spiciate, price a find must be not proposed proposed price and the communication of the co

PTO/\$8/088 (09-06)

Approved for use through 93/31/2007. OMB 9651-4031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO Application Number 10/574.054 INFORMATION DISCLOSURE Filing Date March 29, 2006 STATEMENT BY APPLICANT First Named Inve Shue, Youe-Kong Árt Unit TBA (Use as many sheets as necessary) Examiner Name TRA Sheet 3 of 3 Attorney Docket Number 8031-013-US

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the larm (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SMITH et. al. J Rheumatol 1997; 24:365-71	
		SETNIKER et. al. Arzneimittelforschung 2001; 51:699-725	
		SILVER et. al. Crit Rev Biomed Eng 2001; 29:373-91	
		SAH et. al. J Orthop Res 1997 Mar;15:197-203	
		YOSHIOKA et. al. Osteoarthritis Cartilage 1996; 4:87-98	Г
			Г

Examiner
Signature

Date
Considered

Consi

considered. Include copy of this form with next communication to applicant.

considered. In Chair day of the first in final commissionals be updated.

1. "Application in grad and chair day of the commissional and the property of the commissional and the